🇺🇸 FDA
Patent

US 7378093

Broadly cross-reactive neutralizing antibodies against Human Immunodeficiency Virus selected by Env-CD4-co-receptor complexes

granted A61KA61K2039/505A61P

Quick answer

US patent 7378093 (Broadly cross-reactive neutralizing antibodies against Human Immunodeficiency Virus selected by Env-CD4-co-receptor complexes) held by The United States of America, as represented by the Department of Health and Human Services expires Mon May 22 2028 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Department of Health and Human Services
Grant date
Tue May 27 2008 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 22 2028 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
15
CPC classes
A61K, A61K2039/505, A61P, A61P31/14, A61P31/18